The Treatment of Ledipasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus: The Results of Five-year Follow-up

Basit Öğe Kaydı
dc.contributor.authorPekgöz, Murat
dc.contributor.authorİnce, Nevin
dc.date.accessioned2023-07-26T11:58:20Z
dc.date.available2023-07-26T11:58:20Z
dc.date.issued2021
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractObjectives: Chronic hepatitis C virus (HCV) is a fundamental worldwide health challenge. We assessed the treatment outcomes of ledipasvir (LDV) and sofosbuvir (SOF) with and without ribavirin (RBV) for 12 and 24 weeks in pre-treated and treatment-naive patients with chronic HCV. Materials and Methods: Totally 65 patients were included in the present study. Patients were divided in two groups. In the first group, LDV and SOF with RBV were administered to 12 patients for 12 weeks. In the second group, LDV and SOF without RBV were administered to 53 patients for 24 weeks. Results: Sustained virological response (SVR) rates were 100% for the both groups included in the study. The adverse events were weakness (15.39%), pruritus (6.15%), myalgia (4.62%) nausea (3.08%), dry mouth (1.54%) and anorexia (1.54%) in all patients. HCV-RNA was also negative in all patients 48 weeks after the beginning of the treatment. At the end of the fifth year of treatment, all the patients still had SVR and no recurrence was detected. Conclusion: In the treatment of patients with chronic HCV, LDV and SOF with and without RBV were highly effective. SVR rate of 100% was achieved in all pre-treated or treatment naive patients with or without cirrhosis regardless of genotype of HCV.en_US
dc.identifier.doi10.4274/vhd.galenos.2021.2021-6-1
dc.identifier.endpage130en_US
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue3en_US
dc.identifier.startpage124en_US
dc.identifier.trdizinid507572en_US
dc.identifier.urihttps://doi.org/10.4274/vhd.galenos.2021.2021-6-1
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/507572
dc.identifier.urihttps://hdl.handle.net/20.500.12684/13461
dc.identifier.volume27en_US
dc.identifier.wosWOS:000735716400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorİnce, Nevin
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectChronic Hepatitis C Virus; Direct-Acting Antiviral Agents; Sofosbuvir; Ledipasviren_US
dc.subjectFixed-Dose Combination; Genotype 1 Infection; Long-Term Outcomes; Sofosbuvir; Hcv; Ledipasvir; Ribavirin; Efficacyen_US
dc.titleThe Treatment of Ledipasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus: The Results of Five-year Follow-upen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
133461.pdf
Boyut:
184.05 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu